Insider Transactions in Q2 2021 at Generation Bio Co. (GBIO)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
58
-4.4%
|
$1,508
$26.08 P/Share
|
|
Jun 24
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
30,950
-93.39%
|
$804,700
$26.08 P/Share
|
|
Jun 24
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
31,008
-48.9%
|
$806,208
$26.08 P/Share
|
|
Jun 23
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
116
-7.71%
|
$2,900
$25.39 P/Share
|
|
Jun 23
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
62,493
-42.18%
|
$1,562,325
$25.39 P/Share
|
|
Jun 23
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
62,609
-24.94%
|
$1,565,225
$25.39 P/Share
|
|
Jun 22
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
108
-6.26%
|
$2,592
$24.98 P/Share
|
|
Jun 22
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
58,469
-21.57%
|
$1,403,256
$24.98 P/Share
|
|
Jun 22
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
58,577
-13.92%
|
$1,405,848
$24.98 P/Share
|
|
Jun 21
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
118
-5.9%
|
$2,832
$24.97 P/Share
|
|
Jun 21
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
63,774
-15.12%
|
$1,530,576
$24.97 P/Share
|
|
Jun 21
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
63,892
-10.51%
|
$1,533,408
$24.97 P/Share
|
|
Jun 16
2021
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
100,000
-7.32%
|
-
|
|
Jun 16
2021
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,000,000
-10.97%
|
-
|
|
Jun 15
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$42,000
$28.08 P/Share
|
|
Jun 15
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$6,000
$4.59 P/Share
|
|
Jun 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
6,000
-2.94%
|
$162,000
$27.23 P/Share
|
|
Jun 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+2.86%
|
$24,000
$4.59 P/Share
|
|
May 27
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$51,000
$34.05 P/Share
|
|
May 27
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$6,000
$4.59 P/Share
|
|
May 11
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
400
-0.2%
|
$12,400
$31.05 P/Share
|
|
May 11
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+0.1%
|
$800
$2.6 P/Share
|
|
May 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
8,600
-1.4%
|
$266,600
$31.2 P/Share
|
|
May 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,600
+3.99%
|
$0
$0.6 P/Share
|
|
May 03
2021
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.42%
|
$350,000
$35.9 P/Share
|
|
May 03
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-89.8%
|
$87,500
$35.92 P/Share
|
|
May 03
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$10,000
$4.59 P/Share
|
|
Apr 23
2021
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.84%
|
$350,000
$35.1 P/Share
|
|
Apr 22
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$82,500
$33.32 P/Share
|
|
Apr 22
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$10,000
$4.59 P/Share
|
|
Apr 22
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$51,000
$34.03 P/Share
|
|
Apr 22
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$0
$0.6 P/Share
|
|
Apr 21
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$46,500
$31.07 P/Share
|
|
Apr 21
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$0
$0.6 P/Share
|
|
Apr 16
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,500
-0.75%
|
$42,000
$28.03 P/Share
|
|
Apr 16
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.75%
|
$0
$0.6 P/Share
|
|
Apr 14
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
23,413
-72.51%
|
$608,738
$26.59 P/Share
|
|
Apr 14
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
23,413
-72.51%
|
$608,738
$26.59 P/Share
|
|
Apr 13
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
43,145
-38.84%
|
$1,078,625
$25.31 P/Share
|
|
Apr 13
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
43,145
-38.84%
|
$1,078,625
$25.31 P/Share
|
|
Apr 12
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
6,000
-1.48%
|
$156,000
$26.45 P/Share
|
|
Apr 12
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+2.86%
|
$0
$0.6 P/Share
|
|
Apr 12
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
74,124
-29.48%
|
$1,927,224
$26.34 P/Share
|
|
Apr 12
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
74,124
-29.48%
|
$1,927,224
$26.34 P/Share
|
|
Apr 09
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
43,681
-12.01%
|
$1,179,387
$27.96 P/Share
|
|
Apr 09
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
43,681
-12.01%
|
$1,179,387
$27.96 P/Share
|
|
Apr 08
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
43,550
-9.7%
|
$1,219,400
$28.68 P/Share
|
|
Apr 08
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
43,550
-9.7%
|
$1,219,400
$28.68 P/Share
|
|
Apr 07
2021
|
Jason P Rhodes |
SELL
Open market or private sale
|
Indirect |
39,864
-7.5%
|
$1,116,192
$28.84 P/Share
|
|
Apr 07
2021
|
Atlas Venture Associates X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
39,864
-7.5%
|
$1,116,192
$28.84 P/Share
|